Background: The combination of intrapartum inflammation and hypoxic events exacerbate brain injury. Therapeutic hypothermia (HT) is standard care for neonatal encephalopathy (NE) however its benefit in inflammation-sensitized NE is unclear Methods: 12 male newborn piglets received a 2 μg/kg bolus and 1μg/kg/h continuous 52h infusion of LPS, followed 4 h after a bolus by a transient hypoxic-ischemic (HI) insult. Piglets were then randomized to i) Hypothermia (HT, core temperature 33.5
1 to 25 h after HI, rewarmed at 0.5 C/h, n = 6) or ii) Normothermia (NT, n = 6). Continuous multichannel EEG was obtained.
Blood was collected at baseline, and 6 subsequent time points for blood film examination. Magnetic resonance spectroscopy (MRS) was performed at 24 and 48 h post-HI. After 48 h, histological brain specimens were analysed for cell death (TUNEL+), cleaved caspase 3 (CC3), and glial activation markers (IBA1 and GFAP).
Results: 2 HT piglets died before 48h; all NT piglets survived. Comparing HT and NT, there was no difference in HI severity, EEG recovery post-HI and MRS Lactate/N-acetyl aspartate at 24 or 48 h (P ≥ 0.35). TUNEL+ cell death, microglial and astroglial activation/proliferation were not reduced by HT (P = 0.97, 0.81 and 0.89 respectively). HT increased microglial activation in the caudate (P=0.029) and reduced CC3 throughout the brain (P = 0.04). HT suppressed systemic platelet count from 24h (P ≤ 0.005) and diminished leucocytosis.
Conclusions: HT was not neuroprotective based on EEG, MRS and TUNEL counts in inflammation-sensitized NE. Immunosuppressive effects of HT may contribute to reduced efficacy and safety. Neuroprotective therapies with immunomodulatory effects require exploration in inflammation-sensitized NE. The University of Auckland, Liggins Institute, Auckland, New Zealand Email: ruth.martis@wintec.ac.nz Background: There has been a growing interest in the literature to the identification of perceived enablers and barriers to guide effective implementation of practice and behaviour change. The aim of the study was to compare Key Informant Health Professionals' perception of enablers and barriers prior to implementing tighter glycaemic targets for women diagnosed with gestational diabetes mellitus (GDM) to their actual experience at four months after the implementation.
ENABLER AND BARRIER PERCEPTIONS AND EXPERIENCES OF NEW ZEALAND KEY INFORMANT HEALTH PROFESSIONALS' BEFORE AND AFTER IMPLEMENTING TIGHTER GLYCAEMIC TARGETS FOR WOMEN WITH GESTATIONAL DIABETES
Methods: A cross-sectional questionnaire survey was conducted among 60 Key Informant Health Professionals recruited as part of the Target Trial (ACTRN 12615000282583) before the introduction of tighter glycaemic targets for women with GDM from nine District Health Boards in New Zealand. Data were analysed by calculating frequency and corresponding percentage comparing responses to survey questions before and after the introduction of tighter glycaemic targets for women with GDM.
Results: Sixty health professionals completed the same survey before and after implementation. Confusion over which glycaemic targets to use was perceived as the most significant barrier before implementation (27, 45%), compared to after the implementation (1, 2%). This was a surprise finding. Many perceived enablers identified were found not to be effective enablers after the implementation.
Conclusions: Perceived enabler and barrier identification prior to the implementation of tighter glycaemic targets can inform strategic implementation. Attention should be given to the most important perceived enablers and barriers, to facilitate behaviour change. There is controversy surrounding screening for thrombophilias or autoimmune disorders in women with a history of adverse pregnancy outcomes. This comes from both having limited evidence conclusively showing a causative relationship between hypercoagulability or asymptomatic autoantibodies and adverse pregnancy outcomes, in addition to anticoagulant treatments not showing a positive impact on future pregnancy outcomes. Currently, guidelines suggest not screening for the aforementioned reasons, however Davenport & Kutteh identified many physicians screen contrary to this and it has been routine practice for women with a history suggestive of placenta-mediated preterm birth in our specialist Preterm Birth Prevention Clinic.
Methods: A retrospective cohort study. Women who had an autoimmune or thrombophilia screen performed on attending the Preterm Birth Prevention Clinic were identified. Data were extracted from patient files and hospital electronic systems.
Results: To identify what are current screening practices in our Pre-term Birth Prevention Clinic, how often inherited or acquired thrombophilias or asymptomatic autoantibodies are identified, and whether pregnancy management is altered by the findings. Data collection and analysis are ongoing.
Conclusions: To be confirmed.
